Novo Nordisk's Oral Wegovy Clears Its First Hurdle — Now Comes the Price Test
Published on 11/04/2026 at 20:40 | Editorial boerse-global.de
Novo Nordisk shares climbed 6.3% after the Danish drugmaker delivered third-quarter 2026 results ahead of expectations and nudged its full-year guidance higher. The headline beat is only part of the story. What investors are really weighing is whether the company's fast-growing oral obesity franchise can keep carrying the load once deep US list-price cuts take effect.
A quarter built on obesity, not just optimism
Net revenue for the three months reached DKK 79,195 million, with adjusted operating profit of DKK 31,720 million. Stripping out currency effects, adjusted operating profit rose 27% — a gain that points to genuine operating momentum rather than a rosier forecast alone.
Obesity treatments did the heavy lifting. Sales in that segment advanced 22% at constant exchange rates to DKK 26.15 billion, according to Reuters. The Wegovy pill contributed DKK 5.39 billion of that total, comfortably ahead of the DKK 4.62 billion analyst consensus — a 53% jump on the prior quarter.
The pill's performance matters because the injectable version is shrinking. US revenue from injectable Wegovy fell 13% year on year at constant currencies in the third quarter. Taken together, the combined US Wegovy business still grew 21%, evidence that the oral form more than offset the decline in shots during the period.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance improves, but the range cuts both ways
For the full year 2026, Novo now projects adjusted revenue and adjusted operating profit to land anywhere between a 2% decline and 2% growth at constant exchange rates. That is a meaningful upgrade from the previous outlook, which had spanned flat to a 6% drop.
The new band is no guarantee of expansion. Both metrics could still contract over the full year — but growth is now firmly on the table. Reuters notes the guidance assumes international revenue growth alongside a decline in the US, so management is not banking on a uniform rebound across regions.
The price question hanging over 2027
From January 2027, Novo plans to cut US list prices for Wegovy by roughly 50% and for Ozempic by 35%. List prices are not the same as realized revenue, so the announced reductions do not translate one-for-one into a sales hit. Even so, the strong demand for the pill is not enough on its own to rule out pressure from lower prices — and that uncertainty is central to how the quarter should be read.
The most telling gauge is therefore the combined US Wegovy top line, not the pill in isolation. Whether that combined business can keep adding volume and continue to overcompensate for weaker injectable sales is the question that will define the investment case.
New patients offer a bullish path
One data point supports the more constructive view. According to a BioSpace report published today, 80% of patients who started on the Wegovy pill had not been treated previously. If Novo can sustainably reach additional patients, the oral format could open a growth path of its own rather than simply cannibalizing the injectable.
That scenario, however, requires the broadening to persist — and for added demand to stay strong enough to absorb lower revenue per treatment. A prescription pause would sharpen the problem. Citi data show the four-week average of Wegovy pill prescriptions was nearly flat in the week to 23 October. That is not proof of a lasting stall, but it does temper what the strong quarterly figure can tell us.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Legal setback and the next catalyst
Separately, Novo suffered a courtroom reverse on 26 October, when US federal judge Zahid Quraishi declined its request for a preliminary injunction against challenged comparative advertising by Eli Lilly for its obesity drugs. The ruling addressed only the requested temporary ad block, not the underlying claims of misleading promotion.
Looking further out, an expected FDA decision on CagriSema before the end of 2026 is the next concrete catalyst. Novo plans a US launch in early 2027, contingent on a positive verdict. Approval could widen the future product base, though it would not pre-empt the drug's commercial success.
Two distinct tests thus sit before shareholders: the approval as a possible expansion of the offering, and the revenue trajectory as proof of its economic viability. For the growth thesis, what will ultimately count is whether Novo can convert additional demand into durable sales — even under the coming price regime.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
